It is now important for the European Medicines Agency to recognize and integrate into its regulatory processes these new methods of in silico simulation and prediction.
François-Henri BOISSEL introducing NOVA at Labiotech Refresh 2017, Berlin.
Specify the optimal duration which helps to obtain the target effect, the dose that has to be used to maximize this effect. In other words, it’s to help us do the operations that are done today by a rather theoretical approach.
Pioneer of in silico medicine, NOVADISCOVERY enables its academic and industrial partners to accelerate and de-risk the research and development of new drugs by establishing their therapeutic benefit upstream of human trials.
The Effect Model enables us -according to the indicators that you have, either clinical, genetic, imaging or biomarkers, – to go down to the patient and to go much further in an individual prescription.